317 582

Cited 14 times in

Advanced pharmacotherapy evidenced by pathogenesis of autism spectrum disorder.

DC Field Value Language
dc.contributor.author천근아-
dc.date.accessioned2015-12-28T11:09:17Z-
dc.date.available2015-12-28T11:09:17Z-
dc.date.issued2014-
dc.identifier.issn1738-1088-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/138812-
dc.description.abstractIn clinical practice, pharmacological treatment is mostly focused on behavioral symptoms in everyday life. Nevertheless, persistent effort continues to develop medication for causal treatment. Recent changes in diagnostic criteria from Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) to DSM-5 would affect not only diagnosing approaches, but also therapeutic approaches. Because previous pervasive developmental disorders have been integrated into a single entity, the autism spectrum disorder (ASD), we have to prepare for what medications are valuable for the ASD. In this article, we reviewed the following etiological treatment: acetylcholine and glutamate related medicine; amino acid medicine such as secretin, endogenous opioid, and oxytocin; complementary and alternative medicine such as chelating agents, vitamins, and omega-3; promising drugs related to the scope of pharmacogenetics currently under study.-
dc.description.statementOfResponsibilityopen-
dc.format.extent19~30-
dc.relation.isPartOfCLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleAdvanced pharmacotherapy evidenced by pathogenesis of autism spectrum disorder.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Psychiatry (정신과학)-
dc.contributor.googleauthorYeon Jung Lee-
dc.contributor.googleauthorSoo Hyun Oh-
dc.contributor.googleauthorChanmin Park-
dc.contributor.googleauthorMinha Hong-
dc.contributor.googleauthorAh Rah Lee-
dc.contributor.googleauthorHee Jeong Yoo-
dc.contributor.googleauthorChan Young Shin-
dc.contributor.googleauthorKeun Ah Cheon-
dc.contributor.googleauthorGeon Ho Bahn-
dc.identifier.doi10.9758/cpn.2014.12.1.19-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA04027-
dc.relation.journalcodeJ00609-
dc.identifier.eissn2093-4327-
dc.identifier.pmid24851117-
dc.subject.keywordChild development disorders, pervasive-
dc.subject.keywordDrug therapy-
dc.subject.keywordEtiology-
dc.contributor.alternativeNameCheon, Keun Ah-
dc.contributor.affiliatedAuthorCheon, Keun Ah-
dc.citation.volume12-
dc.citation.number1-
dc.citation.startPage19-
dc.citation.endPage30-
dc.identifier.bibliographicCitationCLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, Vol.12(1) : 19-30, 2014-
dc.identifier.rimsid54937-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Psychiatry (정신과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.